Fresenius Kabi acquired a majority stake in mAbxience, which subsequently received European Commission approval for its biosimilars.
1 report, 0 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Fresenius Kabi acquired a majority stake in mAbxience, which subsequently received European Commission approval for its biosimilars.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Fresenius Kabi
company based in Bad Homborg, Germany; offers health products for the critically and chronically ill.
Nothing else this week.
-
Amgen
American multinational biopharmaceutical company
-
Europe
terrestrial continent located in north-western Eurasia
Coverage
Newest first; wire copies grouped- Unknown outlet